The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2001

Filed:

Jun. 08, 1999
Applicant:
Inventors:

Lesley J. Murray, San Jose, CA (US);

Judy C. Young, San Carlos, CA (US);

Assignee:

Systemix, Inc., Palo Alto, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 1/500 ; C12N 1/563 ; A01N 4/304 ; A61K 3/170 ;
U.S. Cl.
CPC ...
C12N 1/500 ; C12N 1/563 ; A01N 4/304 ; A61K 3/170 ;
Abstract

Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34,and CD34,sub-populations (CD34,Lin,, CD34,Thy-1,Lin,, and CD34,Lin,Rh123,). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.


Find Patent Forward Citations

Murray, Lesley. (2001). Methods for use of mpl ligands with primitive human stem cells (U.S. Patent No. 6326205). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/6326205

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…